Managers of the UBS Q-GARP portfolio continue searching for high-quality U.S. growth companies that are trading at attractive valuations. They maintain that recent volatility in the market has had no impact on…
According to a recent analyst report by Janney, the National Institute of Health budget that was approved last Friday could be a big boost for some select biopharma stocks.
According to Merrill Lynch, the health care sector should act as a good hedge against volatility. Even biotech was shown to offer growth at a reasonable price.
The include BioCryst Pharmaceuticals, Exxon Mobil, Fiat Chrysler Automobiles, Hewlett Packard Enterprise, IAMGOLD, Mallinckrodt and Rockwell Collins.
The top analyst upgrades, downgrades and other research calls from Tuesday include Alibaba, Best Buy, Deere, Jinko Solar, Motorola Solutions, Mylan, Redfin and VMware.
The top analyst upgrades, downgrades and other research calls from Friday include Autodesk, IBM, Lumber Liquidators, NVIDIA, Salesforce.com, Symantec, T-Mobile and Wal-Mart.
Pantheon shares saw a huge gain on Monday following the announcement that the company will be acquired by Thermo Fisher Scientific.
Chris Lange Thermo Fisher Scientific said Friday morning that it has agreed to acquire FEI for approximately $4.2 billion in cash.
Paul Ausick These biotech companies stood out from the rest with big moves over the course of the past week.
Affymetrix was absolutely soaring early on Monday on word that it will be acquired. Thermo Fisher Scientific is the buyer.
Chris Lange Tuesday’s top analyst upgrades, downgrades and initiations include CBS, Cisco, Comerica, Twitter, FedEx, Illumina, Linn Energy and NuVasive.
The unexpected reimbursement rate proposals by the Center for Medicaid hit the diagnostic sector on Monday.
Tuesday's top analyst upgrades and downgrades include AcelRx Pharmaceuticals, AECOM, Electronic Arts, Hewlett-Packard, Myriad Genetics and Urban Outfitters.
24/7 Wall St. has compiled a list health care stocks that Merrill Lynch expects to be top performers in 2015.
A new report from Cowen makes the case that a blood test that detects evidence of cancer in the circulation could soon replace the older more traditional biopsy methods.
